Previous Close | 76.08 |
Open | 75.76 |
Bid | 0.00 x 800 |
Ask | 0.00 x 1000 |
Day's Range | 75.76 - 78.46 |
52 Week Range | 57.17 - 89.74 |
Volume | |
Avg. Volume | 5,524,477 |
Market Cap | 97.792B |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | 17.35 |
EPS (TTM) | 4.52 |
Earnings Date | Jul 31, 2023 - Aug 04, 2023 |
Forward Dividend & Yield | 3.00 (3.94%) |
Ex-Dividend Date | Jun 14, 2023 |
1y Target Est | 91.38 |
Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session.
Marion grew up very healthy, never even getting colds or the flu - but that changed as she got older.
AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (NASDAQ:GILD). The license agreement will provide AbTherx rights to Gilead's recently acquired novel transgenic mouse technologies, which were developed by three of the AbTherx founders.
SANTA MONICA, Calif., June 06, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL), which show that outcomes of Tecartus therapy had consistent high complete response (CR) and overall response rates (ORR), regardless of type of prior treatment, including: Bruton's tyrosine kinase inhibitor (BTKi), bendamustine or autologous
Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.
FOSTER CITY, Calif., June 05, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In this exploratory analysis, Trodelvy demonstrated a clinical
SANTA MONICA, Calif., June 05, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significan
Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost...
FOSTER CITY, Calif., & HAYWARD, Calif., June 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. ARC-7 is the first Phase 2, randomized, open-label study evaluating the comb
Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors. Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation. David Jagielski (Bristol Myers Squibb): Bristol Myers Squibb has been paying dividends for more than 90 consecutive years.
FOSTER CITY, Calif. & SANTA MONICA, Calif., June 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15.
After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer.
Gilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing from last year's payment of the same period to...
Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP.
FOSTER CITY, Calif., May 26, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that
FOSTER CITY, Calif., May 25, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:
NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / Gilead Sciences When LJ Mizzi joined Gilead in 2013, she already had a personal connection to the company. "A Gilead medicine saved the life of a loved one, so I was excited to begin a career here ...
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...
Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year. Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.
The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time. Usama Malik, 48, former CFO of Immunomedics Inc, now owned by Gilead Sciences Inc, admitted to a single charge of securities fraud at a hearing before U.S. District Judge John Michael Vazquez in Newark, New Jersey.
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the strength of Gilead and Kite Oncology’s transformative science in hard-to-treat cancers.
FOSTER CITY, Calif., May 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
FOSTER CITY, Calif., & HAYWARD, Calif., May 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into